BeiGene Reports Results of Tislelizumab + CT in P-III RATIONALE 309 Study as 1L Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Shots: The P-III RATIONALE 309 study involves assessing tislelizumab + gemcitabine + cisplatin vs PBO combined with gemcitabine + cisplatin as a 1L treatment in […]